Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.9 USD | -4.52% | -2.56% | -36.45% |
Mar. 25 | Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol | DJ |
Mar. 25 | Sector Update: Health Care Stocks Steady Premarket Monday | MT |
Financials (USD)
Sales 2024 * | 265M | Sales 2025 * | 406M | Capitalization | 360M |
---|---|---|---|---|---|
Net income 2024 * | -69M | Net income 2025 * | 60M | EV / Sales 2024 * | 1.36 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.89 x |
P/E ratio 2024 * |
-4.71
x | P/E ratio 2025 * |
10.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Esperion Therapeutics, Inc.
1 day | -4.52% | ||
1 week | -2.56% | ||
Current month | -29.10% | ||
1 month | -27.48% | ||
3 months | -10.80% | ||
6 months | +145.29% | ||
Current year | -36.45% |
Managers | Title | Age | Since |
---|---|---|---|
Sheldon Koenig
CEO | Chief Executive Officer | 58 | 20-12-14 |
Director of Finance/CFO | 38 | 19-12-31 | |
JoAnne Foody
CTO | Chief Tech/Sci/R&D Officer | 59 | 21-06-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 52 | 22-04-27 | |
J. Carroll
CHM | Chairman | 74 | 22-05-31 |
Alan Fuhrman
BRD | Director/Board Member | 67 | 20-03-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 237 M€ | +2.89% | - | |
0.00% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1.9 | -4.52% | 4,198,930 |
24-04-25 | 1.99 | -6.57% | 5,147,052 |
24-04-24 | 2.13 | +1.91% | 5,684,029 |
24-04-23 | 2.09 | +9.42% | 4,946,560 |
24-04-22 | 1.91 | -2.05% | 4,791,912 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.45% | 360M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- ESPR Stock